
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8033381/publications.pdf Version: 2024-02-01



K C ALLEN CHAN

#	Article	IF	CITATIONS
1	Jagged Ends on Multinucleosomal Cell-Free DNA Serve as a Biomarker for Nuclease Activity and Systemic Lupus Erythematosus. Clinical Chemistry, 2022, 68, 917-926.	3.2	7
2	High-resolution analysis for urinary DNA jagged ends. Npj Genomic Medicine, 2022, 7, 14.	3.8	4
3	Effects of nucleases on cell-free extrachromosomal circular DNA. JCI Insight, 2022, 7, .	5.0	12
4	Single-Molecule Sequencing Enables Long Cell-Free DNA Detection and Direct Methylation Analysis for Cancer Patients. Clinical Chemistry, 2022, 68, 1151-1163.	3.2	22
5	Fetal mitochondrial <scp>DNA</scp> in maternal plasma in surrogate pregnancies: Detection and topology. Prenatal Diagnosis, 2021, 41, 368-375.	2.3	11
6	Convolutional neural network for discriminating nasopharyngeal carcinoma and benign hyperplasia on MRI. European Radiology, 2021, 31, 3856-3863.	4.5	27
7	Jagged Ends of Urinary Cell-Free DNA: Characterization and Feasibility Assessment in Bladder Cancer Detection. Clinical Chemistry, 2021, 67, 621-630.	3.2	24
8	Characteristics of Fetal Extrachromosomal Circular DNA in Maternal Plasma: Methylation Status and Clearance. Clinical Chemistry, 2021, 67, 788-796.	3.2	26
9	Dynamic Changes of Post-Radiotherapy Plasma Epstein–Barr Virus DNA in a Randomized Trial of Adjuvant Chemotherapy Versus Observation in Nasopharyngeal Cancer. Clinical Cancer Research, 2021, 27, 2827-2836.	7.0	13
10	Applications of genetic-epigenetic tissue mapping for plasma DNA in prenatal testing, transplantation and oncology. ELife, 2021, 10, .	6.0	19
11	Single Cell and Plasma RNA Sequencing for RNA Liquid Biopsy for Hepatocellular Carcinoma. Clinical Chemistry, 2021, 67, 1492-1502.	3.2	9
12	Nuclease deficiencies alter plasma cell-free DNA methylation profiles. Genome Research, 2021, 31, 2008-2021.	5.5	4
13	Genome-wide detection of cytosine methylation by single molecule real-time sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	65
14	Restoration of the Oral Microbiota After Surgery for Head and Neck Squamous Cell Carcinoma Is Associated With Patient Outcomes. Frontiers in Oncology, 2021, 11, 737843.	2.8	9
15	Single-molecule sequencing reveals a large population of long cell-free DNA molecules in maternal plasma. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	43
16	Identification and characterization of extrachromosomal circular DNA in maternal plasma. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 1658-1665.	7.1	106
17	Plasma DNA Profile Associated with DNASE1L3 Gene Mutations: Clinical Observations, Relationships to Nuclease Substrate Preference, and InÂVivo Correction. American Journal of Human Genetics, 2020, 107, 882-894.	6.2	37
18	Intravoxel incoherent motion diffusion-weighted imaging for discrimination of benign and malignant retropharyngeal nodes. Neuroradiology, 2020, 62, 1667-1676.	2.2	10

#	Article	IF	CITATIONS
19	Detection and characterization of jagged ends of double-stranded DNA in plasma. Genome Research, 2020, 30, 1144-1153.	5.5	61
20	Quantitative T1ϕMRI of the Head and Neck Discriminates Carcinoma and Benign Hyperplasia in the Nasopharynx. American Journal of Neuroradiology, 2020, 41, 2339-2344.	2.4	6
21	Sequencing Analysis of Plasma Epstein-Barr Virus DNA Reveals Nasopharyngeal Carcinoma-Associated Single Nucleotide Variant Profiles. Clinical Chemistry, 2020, 66, 598-605.	3.2	10
22	Plasma DNA End-Motif Profiling as a Fragmentomic Marker in Cancer, Pregnancy, and Transplantation. Cancer Discovery, 2020, 10, 664-673.	9.4	152
23	Recent Advances in the Development of Biomarkers and Chemoradiotherapeutic Approaches for Nasopharyngeal Carcinoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 270-280.	3.8	5
24	Early Detection of Cancer: Evaluation of MR Imaging Grading Systems in Patients with Suspected Nasopharyngeal Carcinoma. American Journal of Neuroradiology, 2020, 41, 515-521.	2.4	20
25	Methylation analysis of plasma DNA informs etiologies of Epstein-Barr virus-associated diseases. Nature Communications, 2019, 10, 3256.	12.8	52
26	Topologic Analysis of Plasma Mitochondrial DNA Reveals the Coexistence of Both Linear and Circular Molecules. Clinical Chemistry, 2019, 65, 1161-1170.	3.2	19
27	Status of inflammation in relation to health related quality of life in hepatocellular carcinoma patients. Quality of Life Research, 2019, 28, 2597-2607.	3.1	4
28	Complementary roles of MRI and endoscopic examination in the early detection of nasopharyngeal carcinoma. Annals of Oncology, 2019, 30, 977-982.	1.2	52
29	Correlations of health-related quality of life with serum inflammatory indicators IL-8 and mIBI in patients with hepatocellular carcinoma. Cancer Management and Research, 2019, Volume 11, 2719-2727.	1.9	8
30	Liver-derived cell-free nucleic acids in plasma: Biology and applications in liquid biopsies. Journal of Hepatology, 2019, 71, 409-421.	3.7	31
31	Noninvasive Detection of Bladder Cancer by Shallow-Depth Genome-Wide Bisulfite Sequencing of Urinary Cell-Free DNA for Methylation and Copy Number Profiling. Clinical Chemistry, 2019, 65, 927-936.	3.2	34
32	Costâ€effectiveness of Screening for Nasopharyngeal Carcinoma among Asian American Men in the United States. Otolaryngology - Head and Neck Surgery, 2019, 161, 82-90.	1.9	8
33	Distinguishing early-stage nasopharyngeal carcinoma from benign hyperplasia using intravoxel incoherent motion diffusion-weighted MRI. European Radiology, 2019, 29, 5627-5634.	4.5	35
34	Orientation-aware plasma cell-free DNA fragmentation analysis in open chromatin regions informs tissue of origin. Genome Research, 2019, 29, 418-427.	5.5	159
35	Enrichment of fetal and maternal long cellâ€free DNA fragments from maternal plasma following DNA repair. Prenatal Diagnosis, 2019, 39, 88-99.	2.3	8
36	<i>Dnase1l3</i> deletion causes aberrations in length and end-motif frequencies in plasma DNA. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 641-649.	7.1	134

#	Article	IF	CITATIONS
37	Plasma DNA for early cancer detection – opportunities and challenges. Expert Review of Molecular Diagnostics, 2019, 19, 5-7.	3.1	5
38	Development and validation of a risk model integrating plasma Epstein-Barr virus DNA (EBV DNA) level and TNM stage for stratification of nasopharyngeal cancer (NPC) to adjuvant therapy. Annals of Oncology, 2019, 30, ix97-ix98.	1.2	2
39	Ambient Temperature and Screening for Nasopharyngeal Cancer. New England Journal of Medicine, 2018, 378, 962-963.	27.0	18
40	MR Imaging Criteria for the Detection of Nasopharyngeal Carcinoma: Discrimination of Early-Stage Primary Tumors from Benign Hyperplasia. American Journal of Neuroradiology, 2018, 39, 515-523.	2.4	37
41	Prospective evaluation of plasma Epstein–Barr virus DNA clearance and fluorodeoxyglucose positron emission scan in assessing early response to chemotherapy in patients with advanced or recurrent nasopharyngeal carcinoma. British Journal of Cancer, 2018, 118, 1051-1055.	6.4	24
42	Nonâ€invasive prenatal testing for fetal inheritance of maternal <i>β</i> â€thalassaemia mutations using targeted sequencing and relative mutation dosage: a feasibility study. BJOG: an International Journal of Obstetrics and Gynaecology, 2018, 125, 461-468.	2.3	27
43	DNase1 Does Not Appear to Play a Major Role in the Fragmentation of Plasma DNA in a Knockout Mouse Model. Clinical Chemistry, 2018, 64, 406-408.	3.2	34
44	Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?. British Journal of Cancer, 2018, 118, 248-257.	6.4	71
45	Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). Journal of Clinical Oncology, 2018, 36, 1412-1418.	1.6	324
46	Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial. Journal of Clinical Oncology, 2018, 36, 3091-3100.	1.6	147
47	Preferred end coordinates and somatic variants as signatures of circulating tumor DNA associated with hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E10925-E10933.	7.1	140
48	Sequencing-based counting and size profiling of plasma Epstein–Barr virus DNA enhance population screening of nasopharyngeal carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E5115-E5124.	7.1	114
49	Size-tagged preferred ends in maternal plasma DNA shed light on the production mechanism and show utility in noninvasive prenatal testing. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E5106-E5114.	7.1	107
50	Toward harmonization of clinical molecular diagnostic reports: findings of an international survey. Clinical Chemistry and Laboratory Medicine, 2018, 57, 78-88.	2.3	7
51	Liver- and Colon-Specific DNA Methylation Markers in Plasma for Investigation of Colorectal Cancers with or without Liver Metastases. Clinical Chemistry, 2018, 64, 1239-1249.	3.2	60
52	Association Between Serum Folate Level and Toxicity of Capecitabine During Treatment for Colorectal Cancer. Oncologist, 2018, 23, 1436-1445.	3.7	9
53	Combined Count- and Size-Based Analysis of Maternal Plasma DNA for Noninvasive Prenatal Detection of Fetal Subchromosomal Aberrations Facilitates Elucidation of the Fetal and/or Maternal Origin of the Aberrations. Clinical Chemistry, 2017, 63, 495-502.	3.2	16
54	Gestational Age Assessment by Methylation and Size Profiling of Maternal Plasma DNA: A Feasibility Study. Clinical Chemistry, 2017, 63, 606-608.	3.2	14

#	Article	IF	CITATIONS
55	Universal Haplotype-Based Noninvasive Prenatal Testing for Single Gene Diseases. Clinical Chemistry, 2017, 63, 513-524.	3.2	89
56	Genomewide bisulfite sequencing reveals the origin and time-dependent fragmentation of urinary cfDNA. Clinical Biochemistry, 2017, 50, 496-501.	1.9	60
57	COFFEE: controlâ€free noninvasive fetal chromosomal examination using maternal plasma DNA. Prenatal Diagnosis, 2017, 37, 336-340.	2.3	17
58	Single-Stranded DNA Library Preparation Preferentially Enriches Short Maternal DNA in Maternal Plasma. Clinical Chemistry, 2017, 63, 1031-1037.	3.2	24
59	Current State of PCR-Based Epstein-Barr Virus DNA Testing for Nasopharyngeal Cancer. Journal of the National Cancer Institute, 2017, 109, .	6.3	85
60	Clinical Utility of Epstein-Barr Virus DNA Testing in the Treatment of Nasopharyngeal Carcinoma Patients. International Journal of Radiation Oncology Biology Physics, 2017, 98, 996-1001.	0.8	73
61	Quality Materials for Quality Assurance in the Analysis of Liquid Biopsy Samples. Clinical Chemistry, 2017, 63, 1431-1432.	3.2	6
62	Analysis of Plasma Epstein–Barr Virus DNA to Screen for Nasopharyngeal Cancer. New England Journal of Medicine, 2017, 377, 513-522.	27.0	531
63	DNA of Erythroid Origin Is Present in Human Plasma and Informs the Types of Anemia. Clinical Chemistry, 2017, 63, 1614-1623.	3.2	63
64	In Reply to Zoto Mustafayev and Ozyar. International Journal of Radiation Oncology Biology Physics, 2017, 99, 1307.	0.8	2
65	Systematic evaluation of circulating inflammatory markers for hepatocellular carcinoma. Liver International, 2017, 37, 280-289.	3.9	38
66	Pre-examination factors affecting molecular diagnostic test results and interpretation: A case-based approach. Clinica Chimica Acta, 2017, 467, 59-69.	1.1	5
67	A multicenter randomized controlled trial (RCT) of adjuvant chemotherapy (CT) in nasopharyngeal carcinoma (NPC) with residual plasma EBV DNA (EBV DNA) following primary radiotherapy (RT) or chemoradiation (CRT) Journal of Clinical Oncology, 2017, 35, 6002-6002.	1.6	13
68	Cell-free DNA in maternal plasma and serum: A comparison of quantity, quality and tissue origin using genomic and epigenomic approaches. Clinical Biochemistry, 2016, 49, 1379-1386.	1.9	58
69	Second generation noninvasive fetal genome analysis reveals de novo mutations, single-base parental inheritance, and preferred DNA ends. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E8159-E8168.	7.1	142
70	Personalized therapy for hepatocellular carcinoma: Where are we now?. Cancer Treatment Reviews, 2016, 45, 77-86.	7.7	51
71	First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer. JAMA Oncology, 2016, 2, 305.	7.1	201
72	The association between serum folate level and toxicity of capecitabine Journal of Clinical Oncology, 2016, 34, 3566-3566.	1.6	1

#	Article	IF	CITATIONS
73	Clinical utility of plasma Epsteinâ€Barr virus DNA and <i>ERCC1</i> single nucleotide polymorphism in nasopharyngeal carcinoma. Cancer, 2015, 121, 2720-2729.	4.1	43
74	Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1317-25.	7.1	543
75	Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E5503-12.	7.1	579
76	Noninvasive Prenatal Testing by Nanopore Sequencing of Maternal Plasma DNA: Feasibility Assessment. Clinical Chemistry, 2015, 61, 1305-1306.	3.2	44
77	The impact of digital DNA counting technologies on noninvasive prenatal testing. Expert Review of Molecular Diagnostics, 2015, 15, 1261-1268.	3.1	9
78	Detection of Nasopharyngeal Carcinoma by MR Imaging: Diagnostic Accuracy of MRI Compared with Endoscopy and Endoscopic Biopsy Based on Long-Term Follow-Up. American Journal of Neuroradiology, 2015, 36, 2380-2385.	2.4	51
79	Plasma Epstein-Barr virus DNA as a biomarker for nasopharyngeal carcinoma. Chinese Journal of Cancer, 2014, 33, 598-603.	4.9	45
80	Plasma DNA aberrations in systemic lupus erythematosus revealed by genomic and methylomic sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E5302-11.	7.1	105
81	Maternal Plasma RNA Sequencing for Genome-Wide Transcriptomic Profiling and Identification of Pregnancy-Associated Transcripts. Clinical Chemistry, 2014, 60, 954-962.	3.2	80
82	Size-based molecular diagnostics using plasma DNA for noninvasive prenatal testing. Proceedings of the United States of America, 2014, 111, 8583-8588.	7.1	233
83	Commutability of the Epstein-Barr Virus WHO International Standard across Two Quantitative PCR Methods. Journal of Clinical Microbiology, 2014, 52, 3802-3804.	3.9	36
84	Noninvasive Prenatal Diagnosis of Congenital Adrenal Hyperplasia Using Cell-Free Fetal DNA in Maternal Plasma. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1022-E1030.	3.6	270
85	Methy-Pipe: An Integrated Bioinformatics Pipeline for Whole Genome Bisulfite Sequencing Data Analysis. PLoS ONE, 2014, 9, e100360.	2.5	54
86	Early detection of nasopharyngeal carcinoma by plasma Epsteinâ€Barr virus DNA analysis in a surveillance program. Cancer, 2013, 119, 1838-1844.	4.1	137
87	Noninvasive Prenatal Methylomic Analysis by Genomewide Bisulfite Sequencing of Maternal Plasma DNA. Clinical Chemistry, 2013, 59, 1583-1594.	3.2	131
88	Noninvasive Prenatal Determination of Twin Zygosity by Maternal Plasma DNA Analysis. Clinical Chemistry, 2013, 59, 427-435.	3.2	64
89	Noninvasive twin zygosity assessment and aneuploidy detection by maternal plasma DNA sequencing. Prenatal Diagnosis, 2013, 33, 675-681.	2.3	75
90	Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel Sequencing. Clinical Chemistry, 2013, 59, 211-224.	3.2	447

#	Article	IF	CITATIONS
91	High-Resolution Profiling of Fetal DNA Clearance from Maternal Plasma by Massively Parallel Sequencing. Clinical Chemistry, 2013, 59, 1228-1237.	3.2	202
92	An International Collaboration to Harmonize the Quantitative Plasma Epstein-Barr Virus DNA Assay for Future Biomarker-Guided Trials in Nasopharyngeal Carcinoma. Clinical Cancer Research, 2013, 19, 2208-2215.	7.0	149
93	Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 18761-18768.	7.1	363
94	Scanning for Cancer Genomic Changes in Plasma: Toward an Era of Personalized Blood-Based Tumor Markers. Clinical Chemistry, 2013, 59, 1553-1555.	3.2	12
95	Noninvasive Prenatal Molecular Karyotyping from Maternal Plasma. PLoS ONE, 2013, 8, e60968.	2.5	70
96	Prognostication of survival from nasopharyngeal carcinoma by reduction of plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course: A new paradigm of prognostication Journal of Clinical Oncology, 2013, 31, 6015-6015.	1.6	0
97	Nonhematopoietically Derived DNA Is Shorter than Hematopoietically Derived DNA in Plasma: A Transplantation Model. Clinical Chemistry, 2012, 58, 549-558.	3.2	103
98	Clinical Applications of the Latest Molecular Diagnostics in Noninvasive Prenatal Diagnosis. Topics in Current Chemistry, 2012, 336, 47-65.	4.0	6
99	Digital PCR Analysis of Maternal Plasma for Noninvasive Detection of Sickle Cell Anemia. Clinical Chemistry, 2012, 58, 1026-1032.	3.2	179
100	Noninvasive Prenatal Diagnosis of Monogenic Diseases by Targeted Massively Parallel Sequencing of Maternal Plasma: Application to β-Thalassemia. Clinical Chemistry, 2012, 58, 1467-1475.	3.2	157
101	<i>FetalQuant</i> : deducing fractional fetal DNA concentration from massively parallel sequencing of DNA in maternal plasma. Bioinformatics, 2012, 28, 2883-2890.	4.1	65
102	Proteomic analysis reveals platelet factor 4 and beta-thromboglobulin as prognostic markers in severe acute respiratory syndrome. Electrophoresis, 2012, 33, 1894-1900.	2.4	23
103	Noninvasive Prenatal Diagnosis of Fetal Trisomy 21 by Allelic Ratio Analysis Using Targeted Massively Parallel Sequencing of Maternal Plasma DNA. PLoS ONE, 2012, 7, e38154.	2.5	58
104	High Resolution Size Analysis of Fetal DNA in the Urine of Pregnant Women by Paired-End Massively Parallel Sequencing. PLoS ONE, 2012, 7, e48319.	2.5	86
105	Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. BMJ: British Medical Journal, 2011, 342, c7401-c7401.	2.3	641
106	Targeted Massively Parallel Sequencing of Maternal Plasma DNA Permits Efficient and Unbiased Detection of Fetal Alleles. Clinical Chemistry, 2011, 57, 92-101.	3.2	111
107	Noninvasive prenatal diagnosis of hemophilia by microfluidics digital PCR analysis of maternal plasma DNA. Blood, 2011, 117, 3684-3691.	1.4	232
108	Noninvasive Prenatal Diagnosis of Fetal Trisomy 18 and Trisomy 13 by Maternal Plasma DNA Sequencing. PLoS ONE, 2011, 6, e21791.	2.5	243

#	Article	IF	CITATIONS
109	Noninvasive Prenatal Detection of Trisomy 21 by an Epigenetic–Genetic Chromosome-Dosage Approach. Clinical Chemistry, 2010, 56, 90-98.	3.2	115
110	Serologic Antienzyme Rate of Epstein-Barr Virus DNase-Specific Neutralizing Antibody Segregates TNM Classification in Nasopharyngeal Carcinoma. Journal of Clinical Oncology, 2010, 28, 5202-5209.	1.6	35
111	Maternal Plasma DNA Sequencing Reveals the Genome-Wide Genetic and Mutational Profile of the Fetus. Science Translational Medicine, 2010, 2, 61ra91.	12.4	878
112	Cytokine responses in a severe case of glandular fever treated successfully with foscarnet combined with prednisolone and intravenous immunoglobulin. Journal of Medical Virology, 2009, 81, 99-105.	5.0	9
113	Postâ€ŧransplant EBVâ€related lymphoproliferative disorder complicating umbilical cord blood transplantation in patients of adrenoleukodystrophy. Pediatric Blood and Cancer, 2009, 53, 1329-1331.	1.5	5
114	Single-Molecule Detection of Epidermal Growth Factor Receptor Mutations in Plasma by Microfluidics Digital PCR in Non–Small Cell Lung Cancer Patients. Clinical Cancer Research, 2009, 15, 2076-2084.	7.0	371
115	Rapid identification and differentiation of Gram-negative and Gram-positive bacterial bloodstream infections by quantitative polymerase chain reaction in preterm infants*. Critical Care Medicine, 2009, 37, 2441-2447.	0.9	54
116	Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 20458-20463.	7.1	809
117	Use of plasma DNA to predict mortality and need for intensive care in patients with abdominal pain. Clinica Chimica Acta, 2008, 398, 113-117.	1.1	10
118	Quantitative Analysis of the Transrenal Excretion of Circulating EBV DNA in Nasopharyngeal Carcinoma Patients. Clinical Cancer Research, 2008, 14, 4809-4813.	7.0	60
119	Microfluidics Digital PCR Reveals a Higher than Expected Fraction of Fetal DNA in Maternal Plasma. Clinical Chemistry, 2008, 54, 1664-1672.	3.2	396
120	Noninvasive prenatal diagnosis of monogenic diseases by digital size selection and relative mutation dosage on DNA in maternal plasma. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 19920-19925.	7.1	310
121	Quantitative Analysis of Circulating Methylated DNA as a Biomarker for Hepatocellular Carcinoma. Clinical Chemistry, 2008, 54, 1528-1536.	3.2	141
122	Persistent Aberrations in Circulating DNA Integrity after Radiotherapy Are Associated with Poor Prognosis in Nasopharyngeal Carcinoma Patients. Clinical Cancer Research, 2008, 14, 4141-4145.	7.0	68
123	Digital PCR for the molecular detection of fetal chromosomal aneuploidy. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 13116-13121.	7.1	387
124	Cytokine Profile in Fatal Human Immunodeficiency Virus–Tuberculosis–Epstein-Barr Virus–Associated Hemophagocytic Syndrome. Archives of Internal Medicine, 2007, 167, 1901.	3.8	16
125	Circulating tumour-derived nucleic acids in cancer patients: potential applications as tumour markers. British Journal of Cancer, 2007, 96, 681-685.	6.4	61
126	Quantitative aberrations of hypermethylated <i>RASSF1A</i> gene sequences in maternal plasma in preâ€eclampsia. Prenatal Diagnosis, 2007, 27, 1212-1218.	2.3	66

#	Article	IF	CITATIONS
127	Hypermethylated RASSF1A in Maternal Plasma: A Universal Fetal DNA Marker that Improves the Reliability of Noninvasive Prenatal Diagnosis. Clinical Chemistry, 2006, 52, 2211-2218.	3.2	319
128	Clinical Applications of Plasma Epstein-Barr Virus DNA Analysis and Protocols for the Quantitative Analysis of the Size of Circulating Epstein-Barr Virus DNA. , 2006, 336, 111-122.		8
129	Reduced Plasma RNA Integrity in Nasopharyngeal Carcinoma Patients. Clinical Cancer Research, 2006, 12, 2512-2516.	7.0	27
130	Setting Up a Polymerase Chain Reaction Laboratory. , 2006, 336, 11-18.		24
131	Serum Amyloid A Is Not Useful in the Diagnosis of Severe Acute Respiratory Syndrome. Clinical Chemistry, 2006, 52, 1202-1204.	3.2	14
132	Serum Proteomic Fingerprints of Adult Patients with Severe Acute Respiratory Syndrome. Clinical Chemistry, 2006, 52, 421-429.	3.2	83
133	Plasma Epstein-Barr Viral Deoxyribonucleic Acid Quantitation Complements Tumor-Node-Metastasis Staging Prognostication in Nasopharyngeal Carcinoma. Journal of Clinical Oncology, 2006, 24, 5414-5418.	1.6	346
134	Absence of association between angiotensin converting enzyme polymorphism and development of adult respiratory distress syndrome in patients with severe acute respiratory syndrome: a case control study. BMC Infectious Diseases, 2005, 5, 26.	2.9	41
135	Detrimental Effect of Formaldehyde on Plasma RNA Detection. Clinical Chemistry, 2005, 51, 1074-1076.	3.2	5
136	Effects of Preanalytical Factors on the Molecular Size of Cell-Free DNA in Blood. Clinical Chemistry, 2005, 51, 781-784.	3.2	172
137	Investigation into the Origin and Tumoral Mass Correlation of Plasma Epstein–Barr Virus DNA in Nasopharyngeal Carcinoma. Clinical Chemistry, 2005, 51, 2192-2195.	3.2	46
138	Circulating Placental RNA in Maternal Plasma Is Associated with a Preponderance of 5′ mRNA Fragments: Implications for Noninvasive Prenatal Diagnosis and Monitoring. Clinical Chemistry, 2005, 51, 1786-1795.	3.2	59
139	Lack of Dramatic Enrichment of Fetal DNA in Maternal Plasma by Formaldehyde Treatment. Clinical Chemistry, 2005, 51, 655-658.	3.2	52
140	Investigation of the Genomic Representation of Plasma DNA in Pregnant Women by Comparative Genomic Hybridization Analysis: A Feasibility Study. Clinical Chemistry, 2005, 51, 2398-2401.	3.2	4
141	Systematic micro-array based identification of placental mRNA in maternal plasma: towards non-invasive prenatal gene expression profiling. Journal of Medical Genetics, 2004, 41, 461-467.	3.2	122
142	ACE2 Gene Polymorphisms Do Not Affect Outcome of Severe Acute Respiratory Syndrome. Clinical Chemistry, 2004, 50, 1683-1686.	3.2	76
143	Quantitative Analysis of Cell-Free Epstein-Barr Virus DNA in Plasma of Patients with Nonnasopharyngeal Head and Neck Carcinomas. Clinical Cancer Research, 2004, 10, 1726-1732.	7.0	17
144	Diminished Urinary Free Cortisol Excretion in Patients with Moderate and Severe Renal Impairment. Clinical Chemistry, 2004, 50, 757-759.	3.2	77

#	Article	IF	CITATIONS
145	Free Fetal DNA in Maternal Circulation. JAMA - Journal of the American Medical Association, 2004, 292, 2835.	7.4	6
146	Evaluation of Human Chorionic Gonadotropin β-Subunit mRNA Concentrations in Maternal Serum in Aneuploid Pregnancies: A Feasibility Study. Clinical Chemistry, 2004, 50, 1055-1057.	3.2	44
147	Serial Analysis of Plasma Proteomic Signatures in Pediatric Patients with Severe Acute Respiratory Syndrome and Correlation with Viral Load. Clinical Chemistry, 2004, 50, 1452-1455.	3.2	31
148	Tissue and cellular tropism of the coronavirus associated with severe acute respiratory syndrome: an in-situ hybridization study of fatal cases. Journal of Pathology, 2004, 202, 157-163.	4.5	168
149	Size Distributions of Maternal and Fetal DNA in Maternal Plasma. Clinical Chemistry, 2004, 50, 88-92.	3.2	512
150	Distribution of Cell-Free and Cell-Associated Epstein–Barr Virus (EBV) DNA in the Blood of Patients with Nasopharyngeal Carcinoma and EBV-Associated Lymphoma. Clinical Chemistry, 2004, 50, 1842-1845.	3.2	15
151	Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. Journal of Clinical Virology, 2004, 31, 304-309.	3.1	516
152	Genomic characterisation of the severe acute respiratory syndrome coronavirus of Amoy Gardens outbreak in Hong Kong. Lancet, The, 2003, 362, 1807-1808.	13.7	66
153	Cell-free nucleic acids in plasma, serum and urine: a new tool in molecular diagnosis. Annals of Clinical Biochemistry, 2003, 40, 122-130.	1.6	114
154	Serial Analysis of the Plasma Concentration of SARS Coronavirus RNA in Pediatric Patients with Severe Acute Respiratory Syndrome. Clinical Chemistry, 2003, 49, 2085-2088.	3.2	66
155	Serial Analysis of Fetal DNA Concentrations in Maternal Plasma in Late Pregnancy. Clinical Chemistry, 2003, 49, 678-680.	3.2	30
156	Quantitative Analysis and Prognostic Implication of SARS Coronavirus RNA in the Plasma and Serum of Patients with Severe Acute Respiratory Syndrome. Clinical Chemistry, 2003, 49, 1976-1980.	3.2	148
157	Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Research, 2003, 63, 2028-32.	0.9	181
158	Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma. Clinical Cancer Research, 2003, 9, 3254-9.	7.0	132
159	Fetal DNA Clearance from Maternal Plasma Is Impaired in Preeclampsia. Clinical Chemistry, 2002, 48, 2141-2146.	3.2	118
160	Circulating EBV DNA as a tumor marker for nasopharyngeal carcinoma. Seminars in Cancer Biology, 2002, 12, 489-496.	9.6	83
161	Fetal DNA clearance from maternal plasma is impaired in preeclampsia. Clinical Chemistry, 2002, 48, 2141-6.	3.2	34